Low expression of PTK6/Brk predicts poor prognosis in patients with laryngeal squamous cell carcinoma

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Liu, Xue Kui ^a   Zhang, Xin Rui ^a   Zhong, Qian ^a   Li, Man Zhi ^a   Liu, Zhi Min ^a   Lin, Zhi Rui ^a   Wu, Di ^a   Zeng, Mu Sheng ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Laryngeal squamous cell carcinoma; Prognosis; PTK6 Brk

Indexed keywords

BREAST TUMOR KINASE 6; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE 6; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; CYTOPLASM; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNX MUCOSA; LARYNX SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; TUMOR DIFFERENTIATION; WESTERN BLOTTING;

AGED; BASE SEQUENCE; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; DNA PRIMERS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LARYNGEAL NEOPLASMS; MALE; NEOPLASM PROTEINS; PROGNOSIS; PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84874642673     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-59     Document Type: Article

References (29)

1. Mitchell PJ, Barker KT, Martindale JE, Kamalati T, Lowe PN, Page MJ, Gusterson BA, Crompton MR. Cloning and characterization of cDNAs encoding a novel non-receptor tyrosine kinase, BRK, expressed in human breast tumors. Oncogene 1994, 9(8):2383-2390.
2. Schmandt RE, Bennett M, Clifford S, Thornton A, Jiang F, Broaddus RR, Sun CC, Lu KH, Sood AK, Gershenson DM. The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary. Cancer Biol Ther 2006, 5(9):1136-1141. 10.4161/cbt.5.9.2953, 16855388.
3. Petro BJ, Tan RC, Tyner AL, Lingen MW, Watanabe K. Differential expression of the non-receptor tyrosine kinase BRK in oral squamous cell carcinoma and normal oral epithelium. Oral Oncol 2004, 40:1040-1047. 10.1016/j.oraloncology.2004.05.010, 15509496.
4. Zhang P, Ostrander JH, Faivre EJ, Olsen A, Fitzsimmons D, Lange CA. Regulated association of protein kinase B/Akt with breast tumor kinase. J Biol Chem 2005, 280:1982-1991.
5. Lin HS, Berry GJ, Fee WE, Terris DJ, Sun Z. Identification of tyrosine kinases overexpressed in head and neck cancer. Arch Otolaryngol Head Neck Surg 2004, 130:311-316. 10.1001/archotol.130.3.311, 15023838.
6. Aubele M, Auer G, Walch AK, Munro A, Atkinson MJ, Braselmann H, Fornander T, Bartlett JM. PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas. Br J Cancer 2007, 96:801-807. 10.1038/sj.bjc.6603613, 2360069, 17299391.
7. Barker KT, Jackson LE, Crompton MR. BRK tyrosine kinase expression in a high proportion of human breast carcinomas. Oncogene 1997, 15:799-805. 10.1038/sj.onc.1201241, 9266966.
8. Kamalati T, Jolin HE, Mitchell PJ, Barker KT, Jackson LE, Dean CJ, Page MJ, Gusterson BA, Crompton MR. Brk, a breast tumor-derived nonreceptor protein-tyrosine kinase, sensitizes mammary epithelial cells to epidermal growth factor. J Biol Chem 1996, 271:30956-30963. 10.1074/jbc.271.48.30956, 8940083.
9. Fan C, Zhao Y, Liu D, Zhang X, Wang E. Detection of Brk expression in non-small cell lung cancer: clinicopathological relevance. Tumour Biol 2011, 32(5):873-880. 10.1007/s13277-011-0188-z, 21603980.
10. Almadori G, Bussu F, Paludettii G. Predictive factors of neck metastases in laryngeal squamous cell carcinoma. Towards an integrated clinico-molecular classification. Acta Otorhinolaryngol Ital 2006, 26:326-334. 2639989, 17633151.
11. Gourin CG, Conger BT, Sheils WC, Bilodeau PA, Coleman TA, Porubsky ES. The effect of treatment on survival in patients with advanced laryngeal carcinoma. Laryngoscope 2009, 119:1312-1317. 10.1002/lary.20477, 19444887.
12. Johansen LV, Grau C, Overgaard J. Laryngeal carcinoma-multivariate analysis of prognostic factors in 1252 consecutive patients treated with primary radiotherapy. Acta Oncol 2003, 42:771-778. 10.1080/02841860310017595, 14690164.
13. Lohynska R, Slavicek A, Bahanan A, Novakova P. Predictors of local failure in early laryngeal cancer. Neoplasma 2005, 52:483-488.
14. Marioni G, Marchese-Ragona R, Cartei G, Marchese F, Staffieri A. Current opinion in diagnosis and treatment of laryngeal carcinoma. Cancer Treat Rev 2006, 32:504-515. 10.1016/j.ctrv.2006.07.002, 16920269.
15. Nguyen-Tan PF, Le QT, Quivey JM, Singer M, Terris DJ, Goffinet DR, Fu KK. Treatment results and prognostic factors of advanced T3-4 laryngeal carcinoma: the University of California, San Francisco (UCSF) and Stanford University Hospital (SUH) experience. Int J Radiat Oncol Biol Phys 2001, 50:1172-1180. 10.1016/S0360-3016(01)01538-3, 11483326.
16. Garcia-Carracedo D, Rodrigo JP, Astudillo A, Nieto CS, Gonzalez MV. Prognostic significance of lymphangiogenesis in pharyngolaryngeal carcinoma patients. BMC Cancer 2010, 10:416-419. 10.1186/1471-2407-10-416, 2928795, 20698954.
17. Bernldez R, Garcia-Pallares M, Morera E, Lassaletta L, Del Palacio A, Gavilan J. Oncologic and functional results of near-total laryngectomy. Otolaryngol Head Neck Surg 2003, 128(5):700-705. 10.1016/S0194-5998(03)00095-0, 12748564.
18. Aubele M, Walch AK, Ludyga N, Braselmann H, Atkinson MJ, Luber B, Auer G, Tapio S, Cooke T, Bartlett JM. Prognostic value of protein tyrosine kinase 6 (PTK6) for long-term survival of breast cancer patients. Br J Cancer 2008, 99(7):1089-1095. 10.1038/sj.bjc.6604660, 2567077, 18781181.
19. Serfas MS, Tyner AL. Brk, Srm, Frk, and Src42A form a distinct family of intracellular Src like tyrosine kinases. Oncol Res 2003, 13:409-419.
20. Harvey AJ, Crompton MR. The Brk protein tyrosine kinase as a therapeutic target in cancer: Opportunities and challenges. Anticancer Drugs 2004, 15:107-111.
21. Qiu H, Miller WT. Regulation of the nonreceptor tyrosine kinase Brk by autophosphorylation and by autoinhibition. J Biol Chem 2002, 277:34634-34641. 10.1074/jbc.M203877200, 12121988.
22. Derry JJ, Prins GS, Ray V, Tyner AL. Altered localization and activity of the intracellular tyrosine kinase BRK/Sik in prostate tumor cells. Oncogene 2003, 22:4212-4220. 10.1038/sj.onc.1206465, 12833144.
23. Brauer PM, Zheng Y, Wang L, Tyner AL. Cytoplasmic retention of protein tyrosine kinase 6 promotes growth of prostate tumor cells. Cell Cycle 2010, 9(20):4190-4199. 10.4161/cc.9.20.13518, 3055202, 20953141.
24. Joon-Seol B, Seung-Taek L. The human PTK6 interacts with a 23-kDa tyrosine- phosphorylated protein and is localized in cytoplasm in breast carcinoma T-47D cells. J Biochem Mol Biol 2001, 34:33-38.
25. Kamalati T, Jolin HE, Fry MJ, Crompton MR. Expression of the BRK tyrosine kinase in mammary epithelial cells enhances the coupling of EGF signalling to PI 3-kinase and Akt, via erbB3 phosphorylation. Oncogene 2000, 19:5471-5476. 10.1038/sj.onc.1203931, 11114724.
26. Ostrander JH, Daniel AR, Lofgren K, Kleer CG, Lange CA. Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells. Cancer Res 2007, 67:4199-4209. 10.1158/0008-5472.CAN-06-3409, 17483331.
27. Chen HY, Shen CH, Tsai YT, Lin FC, Huang YP, Chen RH. Brk activates rac1 and promotes cell migration and invasion by phosphorylating paxillin. Mol Cell Biol 2004, 24:10558-10572. 10.1128/MCB.24.24.10558-10572.2004, 533963, 15572663.
28. Harvey AJ, Crompton MR. Use of RNA interference to validate Brk as a novel therapeutic target in breast cancer: Brk promotes breast carcinoma cell proliferation. Oncogene 2003, 22:5006-5010. 10.1038/sj.onc.1206577, 12902983.
29. Ma S, Bao JY, Kwan PS, Chan YP, Tong CM, Fu L, Zhang N, Tong AH, Qin YR, Tsao SW, Chan KW, Lok S, Guan XY. Identification of PTK6, via RNA Sequencing Analysis, as a Suppressor of Esophageal Squamous Cell Carcinoma. Gastroenterology 2012, 143(3):675-686. 10.1053/j.gastro.2012.06.007, 22705009.